Thymogen Potential in Immune Cell Regulation

Thymogen appears to be a synthetic dipeptide composed of the two amino acids L-glutamine and L-tryptophan (Glu-Trp). It was originally identified by a team of researchers led by Khavinson et al., and thus it is considered to be one of Khavinson’s peptides.⁽¹⁾

The peptide is considered to be a short, defined fragment intended to reproduce some of the regulatory activity attributed to more complex thymus-derived peptide mixtures such as thymalin.⁽²⁾ Researchers exploring how the immune system is regulated at the cellular level may consider experiments with Thymogen that appear to support lymphocyte behavior and gene activity.

 

Research

Thymogen Structure and General Properties

Thymagen is a dipeptide with the sequence Glu-Trp, meaning it consists of a single peptide bond linking glutamic acid to tryptophan. This is among the simplest possible peptide structures. Small peptides of this kind are generally hypothesized to be capable of entering cells and reaching intracellular compartments more readily than larger ones. This may allow them to interact with targets that are not easily accessible to bigger molecules.

The team of Khavinson et al. has proposed that peptides of just a few amino acids, such as Thymogen, may interact with DNA and with proteins involved in transcription, potentially supporting which genes are switched on or off in a given cell type.⁽¹⁾ Within this model, a dipeptide such as Thymogen is viewed as a signaling molecule that may help guide the molecular activity of immune cells in laboratory models.

Thymogen Interactions with Immune Cell Signaling

Research posits that Thymogen may interact with cellular signaling at the cellular level by interacting with the cyclic nucleotide system, which may involve the intracellular messengers cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP).

These two molecules are widely regarded as key second messengers that may relay signals inside cells and help set the balance between activating and restraining responses, including in immune cells. In experiments using lymphocytes, Demidov et al. examined how Thymogen may have supported cAMP and cGMP levels and the activity of phosphodiesterase enzymes that break cyclic nucleotides down.⁽³⁾

The authors suggest that the actions of Thymogen appeared to be “connected with the cyclic nucleotide system,” and that under conditions of sensitization the cAMP/cGMP ratio tended to shift, with the peptide appearing to support the enzymes responsible for cyclic nucleotide catabolism.

These observations suggest that Thymogen may help adjust the cAMP/cGMP balance in lymphocytes, potentially by acting on phosphodiesterase activity, which is one plausible route through which a small peptide might modulate immune cell signaling.

Thymogen and Lymphocyte Differentiation

A recurring theme across studies is that Thymogen may support the maturation, or differentiation, of T-lymphocytes, which are considered the immune cells that may coordinate many immune responses and that normally mature under the support of the thymus. Because Thymogen is structurally derived from thymic peptide material, researchers have hypothesized that it may act as a regulatory signal supporting the development of these cells.

In a study by Zhuk and Galenok, examining lymphocyte populations under conditions of immune insufficiency, the authors apparently observed that exposure to Thymogen may reduce laboratory signs of secondary immunodeficiency. Specifically, the authors commented that the peptide was associated with an “activation of T-lymphocyte differentiation“.⁽⁴⁾ This suggests that Glu-Trp may support the progression of immature lymphocytes toward more mature, functionally competent states.

Thymogen and Cellular Resistance to Stress

Several laboratory experiments set up to observe research models suggest that Thymogen exposure may be associated with greater cellular resilience under stressful conditions simulated in laboratory settings. For example, Filippova et al. studied the peptide’s potential during reduced oxygen states of cardiac muscle cells and reperfusion.⁽⁵⁾ Such settings are commonly used to probe how cells and tissues cope with metabolic stress.

The authors reported an apparent protective potential and, notably, concluded that this action did not appear to depend on common protective mechanisms such as opiate receptors or on blocking calcium entry into the cells. However, the precise mechanism was not clearly distinguished. A separate line of work has examined Thymogen in the context of microbial challenge models. Notably, Iushchuk et al. reported that the peptide appeared to support nonspecific resistance observed in a research model.⁽⁶⁾

Similarly, in a different model, Khmel’nitskii et al. apparently observed that Thymogen exposure may be associated with a less severe spread of Candida cells in experimental cell cultures, suggesting that the peptide stimulates immunocompetent cells towards better activation and defense.⁽⁷⁾ Overall, this suggests that Thymogen may support the functional capacity of immune cells when they are placed under different challenges.

Thymogen and Modulation of Abnormal Cell Growth

Several authors have explored whether Thymogen’s apparent immune-regulating properties might have the potential to regulate abnormal cell proliferation.  Notably, Bespalov et al. examined the peptide in a model of tumor cells. They reported that Thymogen exposure was associated with a modest reduction in tumor cell occurrence by about 12% and a roughly 1.7-fold decrease in the average number of tumors per model.⁽²⁾

In a related radiation-based model, Anisimov et al. suggested that Thymogen appeared to mitigate radionuclide-induced carcinogenesis amongst the cell cultures, again with a decrease in overall tumor cell occurrence.⁽⁸⁾ These observations may be interpreted as consistent with the broader hypothesis that a peptide capable of supporting immune cell function and gene activity might, in turn, be associated with reduced abnormal cell growth in certain models.

NOTE: These products are intended for laboratory research use only. This peptide is not intended for personal use. Please review and adhere to our Terms and Conditions before ordering.

 

References:

1. Khavinson VK, Lin’kova NS, Tarnovskaya SI. Short peptides regulate gene expression. Bull Exp Biol Med. 2016 Dec;162(2):288-292. doi: 10.1007/s10517-016-3596-7. PMID: 27909961.
2. Bespalov VG, Troian DN, Petrov AS, Morozov VG, Khavinson VKh. [Inhibiting effect of thymogen on the development of tumors of the esophagus and forestomach induced by N-nitrososarcosine ethyl ester in rats]. Eksp Onkol. 1989;11(4):23-6. Russian. PMID: 2759010.
3. Demidov SV, Kostromin AN, Kuĭbeda VV, Chernaia IV, Borovok MI. [Effect of thymagen, thymalin and vilosen on the cAMP and cGMP levels and phosphodiesterase activity in spleen lymphocytes during sensitization and anaphylactic shock]. Ukr Biokhim Zh (1978). 1991 Jul-Aug;63(4):104-6. Russian. PMID: 1659006.
4. Zhuk EA, Galenok VA. [Thymogen in the treatment of type-1 diabetes mellitus]. Ter Arkh. 1996;68(10):12-4. Russian. PMID: 9026934.
5. Filippova OV, Reznikov KM, Alabovskiĭ VV, Khamburov VV, Vinokurov AA. [The effect of thymogen on the heart in ischemia and reperfusion]. Eksp Klin Farmakol. 1997 May-Jun;60(3):27-9. Russian. PMID: 9324392.
6. Iushchuk ND, Tseneva GIa, Alenushkina TV, Kuliashova LB. [The efficacy of using thymogen in an experimental infection caused by Yersinia enterocolitica]. Zh Mikrobiol Epidemiol Immunobiol. 1995;(3):106-8. Russian. PMID: 7660690.
7. Khmel’nitskiĭ OK, Iakovlev GM, Belianin VL, Khavinson VKh, Morozov VG, Deĭgin VI. [The effect of a synthetic thymus peptide (thymogen) on the immune system in candidiasis under immunodepression]. Arkh Patol. 1990;52(1):20-5. Russian. PMID: 2337388.
8. Anisimov VN, Miretskiĭ GI, Morozov VG, Pavel’eva IA, Khavinson VKh. [The effect of the synthetic immunomodulator thymogen on radiation-induced carcinogenesis in rats]. Vopr Onkol. 1992;38(4):451-8. Russian. PMID: 1300740.